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ABSTRACT 
Human African trypanosomiasis (HAT) is a neglected tropical disease, with a 
population of 70 million at risk. Current treatment options are limited. In the search 
for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug 
fexinidazole has completed Phase III trials with the anticipation that it will be the first 
oral treatment for HAT.  
 
This study used the recently validated bioluminescence imaging model to assess the 
dose and rate of kill effect of fexinidazole in infected mice, and the dose-dependent 
effect of fexinidazole on trypanosome infection. Pharmacokinetics of fexinidazole in 
plasma and central nervous system (CNS) compartments were similar in both 
infected and uninfected mice. Drug distribution within the CNS was further examined 
by microdialysis, showing similar levels in the cortex and hippocampus. However, 
high variability in drug distribution and exposure was found between mice.  
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1. Introduction 
Human African trypanosomiasis (HAT) is caused by Trypanosoma brucei sspp. 
Manifestation of ‘sleeping sickness’, or chronic-stage HAT, occurs when the 
parasites migrate into the central nervous system (CNS). Although fewer than 7000 
cases are reported each year, nearly 70 million people remain at risk [1]. Current 
therapies are limited by toxicity, route of administration and stage-specific activities 
[2]. Two drugs are currently undergoing clinical trials: fexinidazole and the oxaborole 
SCYX-7158 [3]. 
 
Fexinidazole, which offers a potential new safe oral treatment, was rediscovered 
during a screening programme against T. brucei by the Drugs for Neglected 
Diseases Initiative in 2005 [4], and completed Phase II/III trials for the treatment of 
chronic-stage HAT in April 2015 [5,6], with drug registration planned by the end of 
2016 [7]. Preclinical studies showed oral effectiveness in curing both chronic and 
acute stages of the disease in mice [8]. Fexinidazole is metabolized rapidly by a 
range of cytochrome P450 enzymes, including CYPs 1A2, 2B6, 2C19, 3A4 and 3A5, 
and flavin-containing mono-oxygenase into two active metabolites: fexinidazole 
sulfoxide and fexinidazole sulfone [6,8,9].  
 
The recently completed Phase II/III clinical trials performed in Africa compared the 
safety and efficacy of fexinidazole treatment with that of the combination therapy 
NECT (nifurtimox and eflornithine) [3]. The 10-d oral fexinidazole treatment regimen 
currently being implemented is 1800 mg/d (3 x 600 mg taken with food) for 4 d 
followed by 1200 mg/d for 6 d (2 x 600 mg taken with food). Clinical studies also aim 
to determine if lower doses and shorter treatment regimens can be used [7].  
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Studies on fexinidazole in mice were undertaken to: (i) further validate the use of 
optical imaging [10] in a T. brucei mouse model with acute and chronic infection to 
monitor drug effect in real-time, and measure dose response and time-kill [11]; (ii) 
determine any differences in pharmacokinetics between infected and uninfected 
mice; and (iii) expand pharmacokinetic studies to the CNS using microdialysis to 
provide data on the distribution of fexinidazole and its metabolites. This study aimed 
to provide further knowledge on the relationship between drug exposure, parasite 
distribution and rate of kill, as well as to test the full potential of the mouse imaging 
model. 
 
2. Methods and materials 
2.1. Parasites 
The red-shifted bioluminescent T. b. brucei strain GVR35-VSL-2 [10] was used in all 
infection studies. This parasite strain produces a chronic infection in mice 21 d post-
infection (D21 p.i.), as detailed in previous studies [11]. 
 
2.2. Drug sources 
Fexinidazole was kindly provided by Dr Benedict Blayney, Sanofi, France. 
Fexinidazole sulfone and sulfoxide were generously donated by Dr Stephen 
Patterson from Drug Discovery Unit, University of Dundee, UK.  
  
2.3. Animal models 
The experimental protocol was performed with the approval of the UK Home Office 
Animals (Scientific Procedures) Act 1986 and the London School of Hygiene and 
Tropical Medicine (LSHTM) Ethics Committee. Work undertaken at LSHTM was 
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under the project Licence 70/8427 ‘Biology and control of protozoal infections’. 
Microdialysis experiments were performed at Pharmidex under the Home Office 
Project Licence 70/7723 ‘Discovery ADMET studies for novel therapeutics.’  
 
Female CD1 mice weighing 20–25 g (Charles River Laboratories, Wilmington, MA, 
USA) were housed in specific-pathogen-free individually vented cages, and fed ad 
libitum. Mice were infected with 5 x 103 trypanosomes/mL from a donor mouse by 
the intravenous route, as detailed previously [11], and randomized into three animals 
per cage (two cages = one experimental group). ARRIVE guidelines were adhered to 
in this report [12]. 
 
2.4. Drug dose effect in vivo 
The protocol to assess the drug efficacy of fexinidazole using bioluminescence 
imaging (BLI) has been described previously [11,13]. In brief, infected mice were 
grouped and treated on D21 p.i. with 200, 66.7, 22.2 or 7.4 mg/kg fexinidazole in the 
oral formulation carrier solution methylcellulose (0.5% w/v, Sigma, Gillingham, 
UK)/Tween 80 (5% v/v, Sigma) in sterile H2O. Mice were dosed orally (p.o.) daily for 
5 d. Two control groups were included in the study: an untreated control and a CNS-
positive control in which mice were dosed intraperitoneally (i.p.) with 40 mg/kg 
diminazene aceturate (Sigma) to clear peripheral parasitaemia alone. Mice were 
imaged on D21 (prior to dosing), D25 (after last dose), D28 and D35 on an IVIS 
Lumina II (Perkin Elmer, Wokingham, UK) with the following settings: a set of 
exposure times; 1, 3, 10, 30, 60 and 180 s, a binning of 4, 1 f/stop, an open filter, 
and field of view E (12.5 x 12.5 cm) to provide a qualitative representation of rate of 
kill. Ten minutes prior to imaging, mice were dosed with 150 mg/kg i.p. luciferase 
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substrate, D-Luciferin [Perkin Elmer; diluted in Dulbecco’s phosphate buffered saline 
(PBS)] [13]. 
 
At the end of the experiment, blood was collected via cardiac puncture and mixed 
with a chaotropic salt (guanidine HCl) in a 50/50 solution and stored at 4°C for DNA 
extraction using the High Pure polymerase chain reaction (PCR) template according 
to the manufacturer’s instructions (Roche, Welwyn Garden City, UK). For ex-vivo 
imaging and quantitative PCR analysis of the brains, mice were perfused with PBS 
to remove blood, and the brains were snap frozen on dry ice and stored at -80°C for 
later DNA extraction, also using the Roche High Pure PCR template kit. Using a 
primer sequence to target the invariant surface glycoprotein (ISG-75), parasite 
burden was determined by real-time quantitative PCR using SYBR Green (Applied 
Biosystems, Foster City, CA, USA) incorporation in an ABI Prism 7000 sequence 
detection system (Applied Biosystems) relative to the standard curve using the 
methods detailed previously [11]. 
 
2.5. Pharmacokinetics  
2.5.1. Study details 
Plasma and brain concentration profiles of the parent compound fexinidazole and its 
sulfoxide and sulfone metabolites were determined after oral dosing in both 
uninfected mice and mice infected with T. b brucei GVR35-VSL-2. Infected or 
uninfected mice were allocated at random into groups of three per sampling time 
point, and a single dose of fexinidazole 200 mg/kg was administered orally to both 
groups on D24 p.i. At eight selected time points after dosing (0.25, 0.5, 1, 2, 4, 6, 8 
and 12 h), mice were culled and plasma was collected by centrifugation of 
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heparinized blood at 2000 g for 10 min. The plasma was then snap frozen on dry ice 
and stored at -80C. Brain samples were also collected after perfusion with PBS via 
the hepatic portal vein, before being snap frozen on dry ice and stored at -80C. 
 
2.5.2. Sample preparation 
Brain samples were thawed and homogenized individually with a 1:1 weight:volume 
ratio of 0.1% v/v aqueous formic acid in a Bullet blender model BBY5E (Next 
Advance, Averill Park, NY, USA) for 5 min at speed 8. In a clean microcentrifuge 
tube, 25 L of homogenized brain was added to 100 L of extraction solvent 
(acetonitrile containing 200 ng/mL tolbutamide, an internal standard). The tube was 
vortex agitated for 1 min and centrifuged at 3000 g at 4C for 20 min. The 
supernatant was then collected and stored at -80C.  
 
Plasma samples were thawed, and a 50-L aliquot of each was added to 150 L of 
extraction solvent (as used for brain sample preparation) in a clean microcentrifuge 
tube and vortexed for 1 min. The tube was centrifuged at 3000 g at 4C for 20 min, 
and the supernatant was collected and stored at -80C.  
 
Calibration standards for quantification of analyte concentrations in plasma were 
prepared by spiking aliquots of control plasma with specific amounts of analyte to 
give nominal concentrations over the ranges 1–5000 ng/mL for fexinidazole and 50–
50 000 ng/mL for each of the metabolites. Calibration standards for brain were 
prepared by spiking control brain homogenate to give nominal concentrations over 
the ranges 2–10 000 ng/g for fexinidazole and 10–40 000 ng/g for each of the 
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metabolites. Calibration standards were prepared for analysis alongside study 
samples using the same method. 
 
2.5.3. Brain and plasma sample analysis 
The brain and plasma extracts were analysed for fexinidazole and its sulfoxide and 
sulfone metabolites using an Agilent 1290 UHPLC and autosampler combined with 
an Agilent 6550 QTof iFunnel mass spectrometer (Agilent Technologies, Craven 
Arms, UK). Extracts were thawed and diluted 1:1 with water, and 6-µL aliquots were 
injected on to an Agilent RRHD C18 column (50 mm x 2.1 mm, 1.8 µm) maintained 
at 50 °C in a column oven. Sample components were eluted from the column using a 
mobile phase consisting of aqueous formic acid (0.1% v/v, Channel A) and 
acetonitrile containing 0.1% v/v formic acid (Channel B); a gradient elution 
programme increased the proportion of B from 2% to 95% between 0.5 and 1.3 min 
p.i., maintained at 95% until 2.5 min, before returning to 2% at 2.6 min p.i. 
 
The mass spectrometer was operated in positive ion electrospray mode scanning 
m/z 100–1000 in 0.3 s. The instrument was calibrated before data acquisition, and 
internal references were infused continuously to compensate for any drift during the 
course of the run. Peaks in extracted ion chromatograms [corresponding to the 
expected mass/charge ratios (accurate to four decimal places) of singly protonated 
analyte molecules, with windows of ± 20 ppm] were integrated and quantified against 
calibration curves generated using MassHunter v B.05.01 software (Agilent). 
 
2.6. Microdialysis 
2.6.1. Surgical procedure 
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General anaesthesia was induced using isofluorane (5% in O2) and maintained at 
2% during the surgery. Microdialysis guide cannulae (MAB8, Microbiotech, 
Stockholm, Sweden) were stereotaxically implanted simultaneously into the 
prefrontal cortex (PFC) (AP +2.1, DL −0.5, V −1.0) and the ventral hippocampus 
(VH) (AP −2.9, DL +2.7, V −1.7) (co-ordinates in mm from bregma/dura) [14] of 
female CD1 mice (n=3). Guide cannulae were secured with acrylate cement and a 
tether anchor screw (Instech, Plymouth Meeting, PA, USA) attached. On completion 
of surgery, animals were administered analgesics and subcutaneous saline, and 
placed in an incubator until they regained their righting reflex. Mice were used in 
experiments 48 h after surgery. 
 
 2.6.2. Microdialysis procedure 
Microdialysis was performed according to methodology described previously [15]. On 
the day prior to the experiments, animals were placed in microdialysis cages for 
overnight habituation. The following morning, pins were removed from guide 
cannulae and replaced with microdialysis probes (2 mm Polyether Sulphone 
membrane, MAB8.4.2, Microbiotech, Stockholm, Sweden). Probes were perfused 
with artificial cerebrospinal fluid containing 1% hydroxypropyl-β-cyclodextrin, 145 mM 
NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.2 mM CaCl2 and 10.0 mM Na2HPO4, pH 7.40 at 
1.5 μL/min. After 1 h of equilibration, pre-administration basal microdialysate was 
collected for 20 min. Animals were dosed (5 mL/kg p.o.) with fexinidazole in aqueous 
Tween 80 (5% w/v)/methyl cellulose 400 (0.5% w/v) at 200 mg/kg. Microdialysates 
(45-µL aliquots) were collected in microvials containing acetonitrile (15 µL) using a 
30-min sampling regime for 3.5 h.  
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2.6.3. Analysis of microdialysis samples 
Microdialysis samples were analysed using an Agilent 1200 high-performance liquid 
chromatography system combined with an Agilent 6410A triple quadrupole mass 
spectrometer. A mobile phase of water/0.1% formic acid (Channel A) and 
acetonitrile/0.1% formic acid (Channel B) was used to elute sample components 
from a Kinetex column packed with 5 µm of C18 material (2.1 mm x 50 mm at 50°C). 
The mobile phase composition was held at its initial 5% B for 0.1 min p.i., then 
programmed to increase linearly to 95% B at 1.2 min; after a further 0.5 min at 95% 
B, the composition was returned to its initial 5% B at 1.80 min p.i. Fexinidazole was 
detected monitoring the transition m/z 280.1  m/z 140; its sulfoxide and sulfone 
metabolites were detected monitoring the transitions m/z 296.1  m/z 140 and m/z 
312.1  m/z 140, respectively. 
 
Analyte concentrations were quantified against calibration standards prepared in 
artificial cerebrospinal fluid/acetonitrile, with 4-µL aliquots of sample and standard 
being injected.  
 
3. Results 
3.1.  Drug effect 
VSL-2 infected mice were treated with fexinidazole at 7.4, 22.2, 66.7 and 200 mg/kg, 
six mice per dose [9]. BLI and parasitaemia were assessed prior to treatment on D21 
p.i. and then on D25, 28, 30 and 35 p.i. (Fig. 1).  
 
The BLI data showed that by D25, only the 66.7 mg/kg and 200 mg/kg doses were 
able to reduce the bioluminescence signal (the loss in bioluminescence can be seen 
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in Fig. 1A). The bioluminescence in the 7.4 mg/kg dose group decreased after 
treatment (indicated as blue areas in Fig. 1A), but was above background detection, 
whereas the 22.2 mg/kg dose group exhibited a reduction in bioluminescence, with 
just the highly vascular areas of the nose and feet having a detectable signal. Three 
days later on D28, mice treated with the highest doses of 66.7 and 200 mg/kg 
fexinidazole were still negative for detectable bioluminescence. Relapse of 
trypanosome infection occurred in the mice treated with 7.4 mg/kg fexinidazole on 
D28, with disseminated bioluminescence levels similar to D21, while the 22.2 mg/kg 
dose group also showed increased BLI levels.  
 
By the end of the experiment (D35), three of the four doses had relapsed, with 
relative levels of bioluminescence indicating a dose-dependent effect (Fig. 1B). The 
66.7 mg/kg treatment group, despite showing no detectable bioluminescence 7 d 
earlier on D28 p.i. (Fig. 1A), had early stages of drug relapse, with bioluminescence 
being present throughout the entire animal. Mice treated with 200 mg/kg fexinidazole 
showed no bioluminescence on D35, indicating that the mice were clear of infection.  
 
In order to quantify the dose-dependent effect, the mean bioluminescence of each 
group was determined and shown in relation to days p.i. in Fig. 1B, demonstrating 
that BLI can provide both dose and time-kill effect data. All four doses showed an 
initial drop in bioluminescence from ~1010 photons/s to 2.8 x 109 photons/s (7.4 
mg/kg group), 8.5 x 107 photons/s (22.2 mg/kg group) and to just above background 
at 1 x 106 for mice treated with 66.7 mg/kg and 200 mg/kg fexinidazole. However, at 
the three lowest doses (7.4, 22 and 66.7 mg/kg), bioluminescence increased with the 
re-appearance of the infection after D28.  
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 A rapid drop in bioluminescence from 1010 photons/s to below background detection 
of 6 x 105 photons/s was seen in the mice treated with 200 mg/kg fexinidazole, 
where it remained until the end of the experiment. The initial drop in parasitaemia 
was also detected in blood films (Fig. 1B) after treatment, with all treated groups 
except 7.4 mg/kg fexinidazole (parasitaemia of nine trypanosomes/10 fields of view) 
exhibiting undetectable parasitaemia.  
 
On D28, the mice treated with 7.4 mg/kg fexinidazole had a slight increase in 
parasitaemia to 28 trypanosomes/10 fields of view. Mice treated with 200 mg/kg 
fexinidazole and diminazene aceturate remained blood-film negative until the end of 
the experiment.  
 
On D35, the end of the experiment, both the T. b. brucei GVR35-VSL-2 and wild-
type-infected mice were culled and the perfused brains were removed for 
quantitative PCR analysis to determine parasite burden. The excised brains of the 
VSL-2 mice were also imaged prior to freezing (Fig. 1C). The BLI and quantitative 
PCR data (Fig. 1C) of the excised brains reflected the whole animal imaging; in other 
words, increasing doses of fexinidazole resulted in lower bioluminescence and a 
decrease in parasitic burden.  
 
3.2. Pharmacokinetics of fexinidazole and its metabolites. 
A study to investigate the pharmacokinetics of fexinidazole and its metabolites was 
performed using both infected and uninfected female CD1 mice. A dose of 200 
mg/kg fexinidazole was administered orally, with terminal plasma and brain samples 
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collected at eight time points (n=3/time point). Plasma and brain samples were 
extracted and analysed to generate concentration vs time profiles of the parent 
compound and its two major metabolites.  
 
The profiles are illustrated in Figs 2 (plasma) and 3 (brain), and appeared to be 
broadly consistent with published data [4,16]. Fexinidazole was the least abundant of 
the three components in plasma and brain, but demonstrated good brain penetration 
with brain:plasma concentration ratios of 4.0 for uninfected animals and 1.8 for 
infected animals (based on AUC0–12). Fexinidazole sulfoxide and sulfone plasma 
concentrations were higher than those of unchanged drug, consistent with its 
extensive first-pass metabolism. They were also greater in the brain despite both 
metabolites being considerably less brain penetrant than the parent compound 
(brain:plasma concentration ratios of 0.20 and 0.18 for sulfoxide and 0.15 and 0.13 
for sulfone for uninfected and infected animals, respectively). 
 
The total exposure of fexinidazole and its two main metabolites in plasma and brain 
were similar between the infected and uninfected groups (Tables 1 and 2). There is 
perhaps a suggestion of a trend for exposure in the infected group to be lower, but 
the relatively high variability observed for concentrations at replicate time points 
means that this cannot be confirmed. 
 
3.3.  Microdialysis 
Recovery of fexinidazole in microdialysates was estimated using the in-vitro recovery 
method [16]. In the presence of 1% 2-hydroxypropyl-β-cyclodextrin, recovery of 
fexinidazole was 14.7% at 25 ng/mL and 13.8% at 100 ng/mL. Recoveries for the 
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sulfoxide and sulfone metabolites were not determined, so only qualitative 
comparisons between concentrations of fexinidazole and its metabolites are 
discussed. Concentrations quoted for fexinidazole and its metabolites have all been 
corrected by a factor corresponding to the mean recovery for fexinidazole at the two 
concentrations tested. Concentrations quoted for metabolites may therefore be 
subject to additional error due to the potential for differences in recovery.  
 
The microdialysis studies showed that unbound fexinidazole and its metabolites 
were present in the interstitial fluid (ISF) of both brain regions investigated in this 
study (PFC and VH). Plots of concentration against sampling time (Fig. 4) show fairly 
marked interindividual variability. For example, Mouse 2 showed Cmax for 
fexinidazole of ca. 60 ng/mL in both PFC and VH, with the other two replicates 
showing Cmax of <5 ng/mL. However, concentration vs time profiles within individual 
animals for the three compounds in ISF sampled from PFC and VH showed 
consistent trends. 
 
4. Discussion 
Previous publications [10,17,18] have shown how the BLI mouse model of infection 
for HAT can be used to identify compounds with activity against the CNS stage of 
infection, and significantly shorten the time of the assay. The present study shows 
show how the model can be used to determine: (i) the dose–response effect and rate 
of kill; (ii) the difference in pharmacokinetics of a drug between infected and 
uninfected mice; and (iii) the actual free drug concentrations in the CNS 
compartment using microdialysis.  
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The use of static pharmacokinetic/pharmacodynamic models to evaluate preclinical 
drug profiles has not accounted for drug–parasite interactions or how well the drug 
distributes through both the plasma and tissue [19]. By using a dynamic model that 
looks at the relationship between drug distributions within the plasma and tissue and 
the rate of kill of a drug (concentration and/or time dependent), an understanding of 
drug exposure can be established [20]. By using the bioluminescence model to 
detect the dose-dependent effect of fexinidazole, the time-kill properties of the drug 
during a real-time infection were assessed, showing that fexinidazole is dose 
dependent as relapse occurred early at the lower doses of 22 mg/kg and 66.7 mg/kg. 
 
Comparing the pharmacokinetic profiles of fexinidazole and metabolites between 
both the infected and uninfected mice, it appears that trypanosome infection did not 
alter the metabolism and disposition of fexinidazole significantly. 
 
Both fexinidazole and its sulfoxide metabolite showed two maxima in their 
concentration vs time profiles in both plasma and brain. The first Tmax was ca. 0.5–
1.0 h post-dose with a secondary maximum in concentration at the 6-h time point. 
This was seen in all replicates in both plasma and brain, and is perhaps a 
consequence of a food effect as observed by Tarral et al. [8]. The sulfone metabolite 
showed a single Tmax at 6 h in both plasma and brain, with mean Cmax in uninfected 
animals being approximately twice that in infected animals; this was the only 
indication of a significant difference in pharmacokinetic profiles between the two 
groups (plasma P=0.0012, brain P=0.0376). 
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The microdialysis data suggest that there is a homogenous distribution of 
fexinidazole and its metabolites within the grey matter of the brain, with similar levels 
present in the PFC and VH for individual animals. Large variability in measured 
concentrations of all three drug components was observed between individuals, 
frequently up to and sometimes beyond 10-fold (e.g. the sulfoxide concentrations for 
the 2.0–2.5 h samples were measured as 192, 4093 and 1801 ng/mL in the three 
individuals). Despite there being low variability of concentration profiles for 
fexinidazole and metabolites in the ISF from PFC and VH within animals, there was 
high variability between animals, with Cmax values ranging from 9 ng/mL to 372 
ng/mL for fexinidazole from the PFC. Interindividual variability was also seen in 
human plasma concentrations after the administration of a single dose, and was 
noted to be apparent with the parent and metabolites [8].  
 
Fexinidazole will be used to treat HAT patients with a dose regimen of 1800 mg/d for 
4 d followed by 1200 mg/day for 6 d [8]. It is not possible to relate this to the mouse 
dosing from 200 mg/kg, although there are estimates of allometric scaling of 12 fold 
between human and mouse [21]. Other factors that have an impact, such as BBB 
permeation which differs between infected mice and humans [22], parasite 
distribution and burden, have not been determined.  
 
Fexinidazole has shown promising results in other kinetoplastid diseases, with its 
efficacy also being assessed against Chagas disease and leishmaniasis [23]. 
Studies carried out on Chagas disease found that the active metabolites of sulfoxide 
and sulfone were more effective in curing an acute in-vivo mouse model of T. cruzi 
than the parent drug [23]. In visceral leishmaniasis, both fexinidazole and its 
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metabolites were shown to be effective orally, with good distribution and absorption 
of the drug in the target organs of the liver and spleen [24]. These studies suggest 
that oral fexinidazole has potential as a new treatment for all kinetoplastid diseases.  
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Fig. 1. Bioluminescence imaging to determine dose-dependent effect in vivo. 
Determining fexinidazole drug efficacy using bioluminescence and quantitative 
polymerase chain reaction (PCR). Infected CD1 mice were split into groups of six 
and treated with varying doses of fexinidazole from Day 21 and monitored until Day 
35. (A) A single representative mouse (one mouse from group of six) from each 
dose, showing bioluminescence on a heat map scale (red representing maximum 
flux) before and after treatment. (B) Quantification of bioluminescence and 
parasitaemia by averaging (of six mice) total flux and parasite number, respectively. 
In the top graph, each data point represents the mean ± standard deviation (SD) of 
the bioluminescence analysis as determined by the ROI of the whole animal as 
detailed [13]. Red line indicates background bioluminescence determined from 
bioluminescence imaging of a wild-type-infected mouse. The average microscopic 
counts from Giemsa-stained blood films, each data point is mean ± SD. (C) Ex-vivo 
imaging of perfused brain and related quantitative PCR. Parasite burden determined 
by extraction of DNA from brain homogenates from each of the mice and quantitative 
PCR analysis. Graph shows mean of six mice ± SD of the number of parasites in 50 
ng of DNA. Ex-vivo images were obtained by adding 50 μL of luciferin to perfused 
brains and imaging using the IVIS Lumina II. The detection limit of the quantitative 
PCR was 50 trypanosomes/50 ng of DNA. 
 
Fig. 2. Plasma concentration profiles of fexinidazole and metabolites in infected and 
uninfected mice. Plasma concentration data are presented as the mean (ng/mL) ± 
standard deviation of three mice. A two-way analysis of variance analysis indicates 
that there is no significant difference between concentrations in infected and 
uninfected mice, with the following P values for parent and metabolites; fexinidazole 
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P=0.289, fexinidazole sulfoxide P=0.0627, fexinidazole sulfone P=0.0574. An 
unpaired Student’s t-test was performed to determine the significance between 
fexinidazole sulfone concentrations in infected and uninfected mice at 6 h post dose; 
the analysis showed that there was a significant difference between the two sets of 
data (P=0.0012). **P ≤ 0.01. 
 
Fig. 3. Brain concentration profiles of fexinidazole and metabolites in infected and 
uninfected mice. Brain concentration data are presented as the mean (ng/mL) ± 
standard deviation of three mice. A two-way analysis of variance analysis indicates 
that there is no significant difference between concentrations in infected and 
uninfected mice with the following P values for parent and metabolites; fexinidazole 
P=0.9844, fexinidazole sulfoxide P=0.3605, fexinidazole sulfone P=0.0745. An 
unpaired Student’s t-test was performed to determine the significant difference 
between fexinidazole sulfone concentrations in infected and uninfected mice at 6 h 
post dose; the analysis showed that there was a significant difference between the 
two sets of data (P=0.0376). *P ≤ 0.05. 
 
Fig. 4. Assessment of concentrations of fexinidazole and metabolites in brain 
interstitial fluid (ISF) samples by microdialysis. Two areas of the brain were sampled 
serially over 3.5 h: the prefrontal cortex and the ventral hippocampus. ISF 
concentration data (ng/mL) are presented individually for the three mice, with the 
concentrations of each compound corrected for probe recovery of fexinidazole 
(values quoted for metabolites are thus subject to error if recoveries were different 
from that of fexinidazole). (A) Concentration profiles of drug and metabolites within 
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the prefrontal cortex. (B) Concentration profiles of drug and metabolites within the 
ventral hippocampus. 
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Table 1. Total plasma exposure of fexinidazole and metabolites in infected and 7 
uninfected mice 8 
 
Plasma AUC0–12 (h. ng/mL) 
Fexinidazole Sulfoxide Sulfone Summary 
Uninfected 514 77093 182322 259929 
Infected 1371 70065 120312 191748 
 9 
 10 
 11 
Table 2. Total brain exposure of fexinidazole and metabolites in infected and uninfected 12 
mice 13 
 
Brain AUC0–12 (h. ng/mL) 
Fexinidazole Sulfoxide Sulfone Summary 
Uninfected 2032 15797 27872 45701 
Infected 2401 12283 17423 32107 
 14 
 15 
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